Kodiak Ends Q1 with $169.5M Cash, Operations Supported into 2027
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2026
0mins
Kodiak ended Q1 with $169.5M cash and cash equivalents and believes that current cash and cash equivalents will support operations into 2027. "Kodiak has entered 2026 with continued momentum and increasing clarity as we advance toward key clinical readouts and our first planned regulatory submission," said CEO Victor Perlroth. "The recent positive Phase 3 GLOW2 results for Zenkuda reinforce the strength of our ABC Platform and position us to move forward on our first multi-indication BLA submission. At the same time, we are making meaningful progress across our late-stage portfolio, including continued advancement of KSI-101 and KSI-501, and we eagerly anticipate the September readout for DAYBREAK Phase 3 in wet AMD and the December readout for PEAK Phase 3 in MESI. This year is a defining period for Kodiak, with important opportunities for further clinical validation, regulatory progress and continued evolution of our identity as a vision sciences company".
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KOD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KOD
Wall Street analysts forecast KOD stock price to fall
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 36.220
Low
14.00
Averages
27.86
High
50.00
Current: 36.220
Low
14.00
Averages
27.86
High
50.00
About KOD
Kodiak Sciences Inc. is a precommercial retina-focused biotechnology company. The Company is developing a portfolio of three late-stage clinical programs. Zenkuda (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and, together with KSI-501, is being explored in the BLA-facing Phase 3 DAYBREAK wet AMD study. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Its Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its second investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high prevalence retinal vascular diseases to address the leading unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boxer Capital Increases Stake in Kodiak Sciences Amid Strong Performance
- Stake Increase: Boxer Capital Management increased its stake in Kodiak Sciences by 225,000 shares during Q1 2026, with an estimated transaction value of $5.81 million, indicating strong confidence in the company's future prospects.
- Market Performance: As of May 14, 2026, Kodiak Sciences shares were priced at $38.70, reflecting a staggering 1,000% increase over the past year, significantly outperforming the S&P 500's 25% gain, showcasing market recognition of its potential.
- Financial Position: Kodiak Sciences reported a market value of $51.88 million at the end of Q1, despite a quarterly net loss of $58.2 million; however, the company has $169.5 million in cash, which is expected to fund operations into 2027.
- Clinical Developments: The company is set to announce several clinical trial results, including top-line data for wet AMD in September, and positive outcomes could further drive stock price increases, attracting more investor interest.
See More
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026 for an estimated $17.55 million, indicating strong confidence in the company, particularly as its stock has surged 250% over the past year.
- Quarter-End Position Value: As of March 31, 2026, Boxer Capital's position in Corvus was valued at $16.09 million, reflecting an active investment strategy amidst stock price fluctuations, further solidifying its standing in the biotech sector.
- Financial Overview: Corvus Pharmaceuticals ended Q1 2026 with $236.7 million in cash and marketable securities, with management stating that this funding will support operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: Corvus is conducting a Phase 2 trial expected to enroll approximately 200 patients, with preliminary data showing that 75% of patients maintained effective responses after treatment cessation, indicating potential in immune modulation that may attract further investor interest.
See More
Kodiak Sciences Showcases KSI-101 Clinical Advances
- Clinical Data Consistency: KSI-101 demonstrated rapid and significant visual and anatomical improvements in the U.S. Phase 1b APEX study, with over 50% of patients achieving ≥15-letter gains, and consistent results were observed in the Asian clinical cohort, supporting its potential for global development.
- International Conference Presentations: Kodiak will showcase six poster presentations at the 2026 American Uveitis Society and Association for Research in Vision and Ophthalmology meetings, highlighting KSI-101's clinical progress and applicability across diverse patient populations, thereby enhancing its market recognition.
- New Therapy Development: In addition to KSI-101, Kodiak is advancing KSI-102 and KSI-103, two novel biologic therapies designed to address complex cytokine interactions in chronic inflammatory ocular diseases, showcasing the company's innovative capabilities in the ophthalmic field.
- Market Potential: The development of KSI-101 targets the approximately one million patients affected by macular edema annually, expected to fill the current market gap for effective biologics, presenting significant commercial value and societal impact.
See More
KSI-101 Clinical Results Support Global Development
- Clinical Consistency: KSI-101's results in Asian clinical trials align closely with those from the U.S. Phase 1b APEX study, with 58% of patients achieving a ≥15-letter improvement in visual acuity over 24 weeks, indicating its applicability across diverse patient populations and supporting further global development.
- Multi-Target Therapy Advancement: Kodiak is advancing KSI-102 and KSI-103, novel bispecific therapies designed to address complex cytokine interactions in chronic ocular inflammatory diseases, suggesting significant potential for enhanced therapeutic outcomes beyond current single-target therapies.
- ABCD Platform Innovation: The evolving ABCD platform from Kodiak integrates small molecules and other drugs, showcasing its potential for targeted, multi-modal drug development in retinal and glaucoma optic neuropathy, which could transform the landscape of ocular treatments.
- International Conference Presentations: Kodiak will present its clinical advancements at the 2026 American Uveitis Society and Association for Research in Vision and Ophthalmology meetings, enhancing collaboration and engagement with peers to deepen scientific research and development efforts.
See More
Healthcare Stocks Rise, Market Reacts Positively
- Healthcare Stocks Surge: Late Wednesday afternoon, healthcare stocks rose significantly, driven by the NYSE Health Care Index, indicating a rebound in market confidence towards the sector, possibly reflecting investor optimism regarding future healthcare policies.
- Positive Market Reaction: The rise in healthcare stocks has improved investor sentiment, which may attract more capital into the sector, further driving up stock prices of related companies and enhancing market vitality.
- Optimistic Industry Outlook: The growth potential of the healthcare industry has captured investor attention, particularly in areas of new drug development and medical technology innovation, which are expected to yield substantial revenue growth for related firms.
- Increased Investor Confidence: The uptick in healthcare stocks not only reflects the current positive market sentiment but may also signal signs of future economic recovery, further bolstering investor confidence in long-term investments within the healthcare sector.
See More
Kodiak Sciences Reports Q4 Results and Cash Position
- Earnings Report: Kodiak Sciences reported a Q4 GAAP EPS of -$1.04, aligning with market expectations, indicating financial stability despite ongoing losses.
- Cash Reserves: As of the end of 2025, Kodiak had $209.9 million in cash and cash equivalents, which is projected to support current and planned operations into 2027, bolstering investor confidence in the company's operational sustainability.
- Clinical Progress: Kodiak's stock rose following a successful late-stage trial for diabetic retinopathy therapy, highlighting the company's research potential and competitive position in the ophthalmic disease market.
- Market Sentiment: Despite the stock's rise due to positive eye disease data, analysts remain cautious about Kodiak's future performance, advising investors to stay on the sidelines, reflecting concerns over the company's long-term profitability.
See More
Boxer Capital Increases Stake in Kodiak Sciences Amid Strong Performance
- Stake Increase: Boxer Capital Management increased its stake in Kodiak Sciences by 225,000 shares during Q1 2026, with an estimated transaction value of $5.81 million, indicating strong confidence in the company's future prospects.
- Market Performance: As of May 14, 2026, Kodiak Sciences shares were priced at $38.70, reflecting a staggering 1,000% increase over the past year, significantly outperforming the S&P 500's 25% gain, showcasing market recognition of its potential.
- Financial Position: Kodiak Sciences reported a market value of $51.88 million at the end of Q1, despite a quarterly net loss of $58.2 million; however, the company has $169.5 million in cash, which is expected to fund operations into 2027.
- Clinical Developments: The company is set to announce several clinical trial results, including top-line data for wet AMD in September, and positive outcomes could further drive stock price increases, attracting more investor interest.
See More
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026 for an estimated $17.55 million, indicating strong confidence in the company, particularly as its stock has surged 250% over the past year.
- Quarter-End Position Value: As of March 31, 2026, Boxer Capital's position in Corvus was valued at $16.09 million, reflecting an active investment strategy amidst stock price fluctuations, further solidifying its standing in the biotech sector.
- Financial Overview: Corvus Pharmaceuticals ended Q1 2026 with $236.7 million in cash and marketable securities, with management stating that this funding will support operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: Corvus is conducting a Phase 2 trial expected to enroll approximately 200 patients, with preliminary data showing that 75% of patients maintained effective responses after treatment cessation, indicating potential in immune modulation that may attract further investor interest.
See More
Kodiak Sciences Showcases KSI-101 Clinical Advances
- Clinical Data Consistency: KSI-101 demonstrated rapid and significant visual and anatomical improvements in the U.S. Phase 1b APEX study, with over 50% of patients achieving ≥15-letter gains, and consistent results were observed in the Asian clinical cohort, supporting its potential for global development.
- International Conference Presentations: Kodiak will showcase six poster presentations at the 2026 American Uveitis Society and Association for Research in Vision and Ophthalmology meetings, highlighting KSI-101's clinical progress and applicability across diverse patient populations, thereby enhancing its market recognition.
- New Therapy Development: In addition to KSI-101, Kodiak is advancing KSI-102 and KSI-103, two novel biologic therapies designed to address complex cytokine interactions in chronic inflammatory ocular diseases, showcasing the company's innovative capabilities in the ophthalmic field.
- Market Potential: The development of KSI-101 targets the approximately one million patients affected by macular edema annually, expected to fill the current market gap for effective biologics, presenting significant commercial value and societal impact.
See More
KSI-101 Clinical Results Support Global Development
- Clinical Consistency: KSI-101's results in Asian clinical trials align closely with those from the U.S. Phase 1b APEX study, with 58% of patients achieving a ≥15-letter improvement in visual acuity over 24 weeks, indicating its applicability across diverse patient populations and supporting further global development.
- Multi-Target Therapy Advancement: Kodiak is advancing KSI-102 and KSI-103, novel bispecific therapies designed to address complex cytokine interactions in chronic ocular inflammatory diseases, suggesting significant potential for enhanced therapeutic outcomes beyond current single-target therapies.
- ABCD Platform Innovation: The evolving ABCD platform from Kodiak integrates small molecules and other drugs, showcasing its potential for targeted, multi-modal drug development in retinal and glaucoma optic neuropathy, which could transform the landscape of ocular treatments.
- International Conference Presentations: Kodiak will present its clinical advancements at the 2026 American Uveitis Society and Association for Research in Vision and Ophthalmology meetings, enhancing collaboration and engagement with peers to deepen scientific research and development efforts.
See More
Healthcare Stocks Rise, Market Reacts Positively
- Healthcare Stocks Surge: Late Wednesday afternoon, healthcare stocks rose significantly, driven by the NYSE Health Care Index, indicating a rebound in market confidence towards the sector, possibly reflecting investor optimism regarding future healthcare policies.
- Positive Market Reaction: The rise in healthcare stocks has improved investor sentiment, which may attract more capital into the sector, further driving up stock prices of related companies and enhancing market vitality.
- Optimistic Industry Outlook: The growth potential of the healthcare industry has captured investor attention, particularly in areas of new drug development and medical technology innovation, which are expected to yield substantial revenue growth for related firms.
- Increased Investor Confidence: The uptick in healthcare stocks not only reflects the current positive market sentiment but may also signal signs of future economic recovery, further bolstering investor confidence in long-term investments within the healthcare sector.
See More
Kodiak Sciences Reports Q4 Results and Cash Position
- Earnings Report: Kodiak Sciences reported a Q4 GAAP EPS of -$1.04, aligning with market expectations, indicating financial stability despite ongoing losses.
- Cash Reserves: As of the end of 2025, Kodiak had $209.9 million in cash and cash equivalents, which is projected to support current and planned operations into 2027, bolstering investor confidence in the company's operational sustainability.
- Clinical Progress: Kodiak's stock rose following a successful late-stage trial for diabetic retinopathy therapy, highlighting the company's research potential and competitive position in the ophthalmic disease market.
- Market Sentiment: Despite the stock's rise due to positive eye disease data, analysts remain cautious about Kodiak's future performance, advising investors to stay on the sidelines, reflecting concerns over the company's long-term profitability.
See More
